Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press10010.17650/2222-1468-2014-0-1-11-14DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORSДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ ГОЛОВЫ И ШЕИUSE OF PREDICTORS TO CHOOSE TREATMENT POLICY FOR THYROID CANCERИСПОЛЬЗОВАНИЕ ФАКТОРОВ ПРОГНОЗА В ВЫБОРЕ ТАКТИКИ ЛЕЧЕНИЯ РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫBrzhezovsky,V. Zh.БржезовскийВ. Ж.
Russian Federation
VBR1980@yandex.ruLomayaM. V.ЛомаяМ. В.
Russian Federation
VBR1980@yandex.ruAketovaT. A.АкетоваТ. А.
Russian Federation
VBR1980@yandex.ruResearch Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowОтделение опухолей черепно-челюстно-лицевой области НИИ клинической онкологии ФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, МоскваResearch Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowНИИ клинической онкологии ФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва150420144111141804201518042015Copyright ©; 2014, Brzhezovsky, V.Z., Lomaya M.V., Aketova T.A.Copyright ©; 2014, Бржезовский В.Ж., Ломая М.В., Акетова Т.А.2014Brzhezovsky, V.Z., Lomaya M.V., Aketova T.A.Бржезовский В.Ж., Ломая М.В., Акетова Т.А.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/100

The paper analyzes the results of treatment in patients with papillary thyroid cancer, by applying a great deal of clinical material. Different prognostic factors have been studied for their influence on the survival of the patients after surgical treatment. The most optimal treatment policy is proposed to be defined for patients with this form of cancer on the basis of the association between the above factors.

В статье на значительном клиническом материале приводится анализ результатов лечения больных папиллярным раком щитовидной железы. Изучено влияние различных факторов прогноза на выживаемость пациентов после проведенного хирургического лечения. Предлагается, основываясь на использовании взаимосвязи указанных факторов, определить наиболее оптимальную тактику лечения больных этой формой рака.

thyroid cancertreatmentprognosisрак щитовидной железылечениепрогноз1. Bilimoria K.Y., Bentrem D.J., Linn J.G. et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery 2007;142(6):906–13 [discussion 913. e1–2].Bilimoria K.Y., Bentrem D.J., Linn J.G. et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery 2007;142(6):906–13 [discussion 913. e1–2].2. Lin J.D., Chen S.T., Hsueh C., Chao T.C. A 29-year retrospective review of papillary thyroid cancer in one institution. Thyroid 2007 Jun;17(6):535–41.Lin J.D., Chen S.T., Hsueh C., Chao T.C. A 29-year retrospective review of papillary thyroid cancer in one institution. Thyroid 2007 Jun;17(6):535–41.3. Mazeh H., Samet Y., Hochstein D. et al. Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. Am J Surg 2011 Jun; 201(6):770–5.Mazeh H., Samet Y., Hochstein D. et al. Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. Am J Surg 2011 Jun; 201(6):770–5.4. Ibrahimpasic T., Nixon I.J., Palmer F.L. et al. Undetectable thyroglobulin after total thyroidectomy in patients with lowand intermediate-risk papillary thyroid cancer – is there a need for radioactive iodine therapy? Surgery 2012;152(6):1096–105.Ibrahimpasic T., Nixon I.J., Palmer F.L. et al. Undetectable thyroglobulin after total thyroidectomy in patients with lowand intermediate-risk papillary thyroid cancer – is there a need for radioactive iodine therapy? Surgery 2012;152(6):1096–105.5. Almeida J.P., Sanabria A.E., Lima E.M., Kowalski L. et al. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck 2011;33(5):686–90.Almeida J.P., Sanabria A.E., Lima E.M., Kowalski L. et al. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck 2011;33(5):686–90.6. Nixon I.J., Ganly J., Patel S.G. et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 2012;151(4):571–9.Nixon I.J., Ganly J., Patel S.G. et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 2012;151(4):571–9.7. Пачес А.И. Опухоли головы и шеи. Кли- ническое руководство. М., 2013. 475 с.Пачес А.И. Опухоли головы и шеи. Кли- ническое руководство. М., 2013. 475 с.8. Романчишен А.Ф. Клиническое обосно- вание показаний к оперативному лечению заболеваний щитовидной железы. Вестник хирургии 1994;1–2:3–6.Романчишен А.Ф. Клиническое обосно- вание показаний к оперативному лечению заболеваний щитовидной железы. Вестник хирургии 1994;1–2:3–6.9. Sosa J.A., Bowman H.M., Tielsch J.M. et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228(3):320–30.Sosa J.A., Bowman H.M., Tielsch J.M. et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228(3):320–30.10. Shah J.P., Loree T.R., Dharker D. et al. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992;164(6):658–61.Shah J.P., Loree T.R., Dharker D. et al. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992;164(6):658–61.11. Nixon I.J., Shah J.P. Well differentiated thyroid cancer: are we over treating our patients? Eur J Surg Oncol 2014 Feb;40(2):129–32.Nixon I.J., Shah J.P. Well differentiated thyroid cancer: are we over treating our patients? Eur J Surg Oncol 2014 Feb;40(2):129–32.12. Haymart M.R., Benerjee M., Stewart A.K. et al. Use of radioactive iodine for thyroid cancer. JAMA 2011;306(7):721–8.Haymart M.R., Benerjee M., Stewart A.K. et al. Use of radioactive iodine for thyroid cancer. JAMA 2011;306(7):721–8.13. Trovisco V., Soares P., Sobrinho-Simões M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006 Jul;37(7):781–6.Trovisco V., Soares P., Sobrinho-Simões M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006 Jul;37(7):781–6.14. Wang W., Zhao W., Wang E.U. et al. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann Surg Oncol 2012 Jan;19(1):31–36.Wang W., Zhao W., Wang E.U. et al. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann Surg Oncol 2012 Jan;19(1):31–36.15. Danilovic D.L., Lima E.U., Domingues R.B. et al. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol 2014;170(4):619–25.Danilovic D.L., Lima E.U., Domingues R.B. et al. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol 2014;170(4):619–25.